


About us Profile Management Scientific Advisory Board Strategic alliances Partners Top articles Publications Platform technologies Nested Chemical Library The concept of Nested Chemical Library Chemical Validation Library Master library Hit finding Allosteric library Allosteric library Developing novel allosteric inhibitors Masterkey The Masterkey concept Masterkeys from the Nested Chemical Library Pharmacophore modeling Scaffold hopping The concept of scaffold hopping Scaffold hopping based lead finding Lead optimization - ADMET Lead generation Lead optimization Experimental ADMET parameters KinaTor Services Hit and lead finding Kinase inhibitor library In vitro biology Lead and ADMET optimization Target fishing Predictive QSAR Custom synthesis Process development Drug discovery Cancer stem cells Drug discovery programs Epilepsy EGFR HIV Influenza Neurogenic inflammation Tuberculosis Contact us

Scientific Advisory Board

Prof. Frank Sams-Dodd

He is Chief Scientific Advisor at Asclepios Bioresearch, CEO at Willingsford Limited and Managing Partner at A Tempo Consulting. He was CEO / VP Preclinical Research at Neurofit SAS / Bionomics Ltd until April 2008 and Head of Psychopharmacololgy at Boehringer Ingelheim GmbH until December 2005. He was the Director of Physiology at Amylin Pharmaceuticals, Inc. in the areas of obesity and metabolic disorders (January 2002 - February 2003). In January 2001 he received a D.Sc. degree from the Medical Faculty, Copenhagen University for his schizophrenia research. He has held positions as Research Fellow at H. Lundbeck A/S, Copenhagen Denmark in the areas of drug discovery and behavioural pharmacology for CNS disorders. In addition to the scientific work he has supplemented his education with MBA courses in organization and strategy at the Copenhagen Business School. He has been Chairman of The World Drug Discovery Summit on several occasions, is Member of the Technology Transfer Committee of the Wellcome Trust and publishes regularly in Drug Discovery Today on drug discovery strategies. Received his master degree from Copenhagen University and his PhD degree from Cornell University, Ithaca, NY USA in neurobiology and physiology.

Prof. Michael Karin

He is currently a Professor of Pharmacology at the School of Medicine, University of California, San Diego, where has been on the faculty since 1987. He has served as a member of the Signal Research Division of Celgene since 1992. Dr. Karin also serves as a member of the National Advisory Council for Environmental Health Sciences and has been an American Cancer Society Research Professor since 1999. He is a leading world authority on signal transduction pathways that regulate gene expression in response to extracellular stimuli. Key achievements include definition of cis elements that mediate gene induction by hormones, cytokines and stress, identification and characterization of the transcription factors that recognize these elements and the protein kinase cascades that regulate their activities. Dr. Karin received his PhD in molecular biology from UCLA and completed his postdoctoral training at the Fox Chase Institute for Cancer Research (Dr. Beatrice Mintz) and the Departments of Medicine and Biochemistry at the University of California, San Francisco (Dr. John Baxter). He has published over 200 scientific articles and is an inventor on over 14 different patents or pending patent applications. Recently Dr. Karin was ranked first worldwide by the Institute of Scientific Information (ISI) in a recent listing of most-cited molecular biology and genetic research papers published in prestigious journals.

Bert Klebl PhD

Bert Klebl is CEO and CSO of the Lead Discovery Center GmbH in Dortmund, Germany. Before the LDC was founded in 2008, he has gathered more than 10 years professional experience in drug discovery and early drug development from various positions in the life-science industry, most recently as Senior Director Discovery Biology and Head of Biology at GPC Biotech. Before that he was Axxima's Vice President Research responsible for discovery and development of the company's portfolio of kinase inhibitors for various therapeutic indications. In previous positions he worked as Project Team Leader and Senior Scientist with Aventis and Hoechst Marion Roussel. A biochemist by training, he earned his PhD in Biochemistry at the University of Konstanz, Germany and did post-doctoral work at the Biotechnology Research Institute of the NRC Canada in Montréal, Canada. In the course of his research work he published more than 30 articles in peer-reviewed journals and is a co-inventor of more than 15 patents and patent applications.

Gerhard Müller PhD

Senior Vice President Medicinal Chemistry at Mercachem BV. He is responsible for strategic expansion into medicinal chemistry services, scientific and technical support of business development activities and scientific marketing at Mercachem. He was the Chief Scientific Officer & Managing Director at Proteros Fragments GmbH until May 2011 and Vice President Drug Discovery at GPC Biotech until June 2008. Dr. Müller joined GPC Biotech in 2005 upon GPC Biotech's acquisition of Axxima Pharmaceuticals, where he held the position of CSO from 2003 to 2005. Prior to his tenure at Axxima Pharmaceutical, Dr. Müller headed the Medicinal Chemistry department at N. V. Organon, the Pharmaceutical Business Unit of Akzo Nobel, from 2001 to2003. Before 2001, Dr. Müller held various positions within Life Science Research at the Central Research Facilities at Bayer AG, which he joined in 1994. He began his professional career as a Medicinal Chemist in the Biomolecular Structure Department of Glaxo Group Research in Verona, Italy. Dr. Müller received his Ph.D. in Organic Chemistry in 1992 from the group of Prof. Dr. Horst Kessler, Technical University of Munich.

Prof. Thomas Schulz

Qualified as a medical doctor in Mainz (1979), obtained his MD in 1980 and initially worked in Internal Medicine. He trained as a medical microbiologist in the Department of Medical Microbiology in Mainz (1981 - 1983) and the Institute of Hygiene in Innsbruck (1983 - 1988). Having completed a postdoctoral thesis ("Habilitation") in 1986, he joined Prof. Robin Weiss group at the Institute of Cancer Research, London, as an EMBO Fellow in 1988. From 1988 until 1995 he worked mainly on HIV-1,2, HTLV-I and KSHV/HHV8 (from 1994). In 1995 he was appointed to a professorial chair in the Dept. Medical Microbiology of The University of Liverpool, where he worked on KSHV/HHV8. Since 2000 he has been heading the Institute of Virology of Hannover Medical School in Hannover, Germany. From 1997 until 2003 Dr. Schulz has been the editor for retroviruses of The Journal of General Virology. He is currently the coordinator of the EU FP6 Integrated Project INCA 'The role of chronic infections in the development of cancer'.

Prof. Andrew Wilks

Chief Scientific Officer, co-CEO, Director and founder of Cytopia and the principal inventor of the 5 patents that Cytopia licensed from the Ludwig Institute for Cancer Research. PhD, University of Glasgow in 1981. Research Fellow at the Friedrich Miescher Institute in Basel, Switzerland between 1980 and 1983. Head, Growth Regulation Laboratory at the Melbourne Branch of the Ludwig Institute for Cancer Research from 1989 until 1997. Has published more than 85 primary research articles and been inventor or co-inventor on 12 Australian patents, 9 granted US patents and 4 PCTs.